Back to today’s briefing

Story perspectives

Mounjaro Outshines Wegovy in NHS Weight Loss Trials

5/12/2025

47 4

Summary

Story summary

Mounjaro has emerged as the leading NHS weight loss injection, surpassing Wegovy in trials by effectively targeting GLP-1 and GIP hormones for significant weight loss. In the U.S., patients grapple with insurance limitations, often relegated to less effective options like Zepbound, highlighting ongoing disparities in access to effective treatments across different demographic groups.

1 of 1

Story summary

Mounjaro has emerged as the leading NHS weight loss injection, surpassing Wegovy in trials by effectively targeting GLP-1 and GIP hormones for significant weight loss. In the U.S., patients grapple with insurance limitations, often relegated to less effective options like Zepbound, highlighting ongoing disparities in access to effective treatments across different demographic groups.